Sept. 17, 2020
The National Institutes of Health has awarded Xunlei Kang, an assistant professor at the University of Missouri School of Medicine, a $1.7 million grant to study whether a drug used to treat Type 2 diabetes can prevent acute myeloid leukemia (AML) from spreading throughout the body.
AML accounts for more than 40% of leukemia-related deaths in the U.S., and most people with the disease die within a few years of diagnosis. Despite the numbers, Kang said there has not been progress in treatment in 40 years because targeting the diseased cells is difficult.
Kang and his team will use a Type 2 diabetes drug to try and delay — or even reverse — AML by targeting only the diseased myeloid stem cells and restraining them inside the bone marrow, which would stop them from entering the bloodstream and invading lymph nodes and other organs.
Film explores grief in the digital age
University of Missouri professors team up to explore how people process loss with today’s digital reminders.
Discovering a passion
Senior Stephanie Scott finds belonging through her research.
NextGen researcher profile: Carolyn Anderson
Carolyn Anderson has spent more than 30 years developing targeted therapies for diseases like cancer and sickle cell disease. See how she will help drive research efforts for NextGen Precision Health.
Part of the frontline discovery group
Undergraduate research opportunities open doors for College of Agriculture, Food and Natural Resources students.
Stay up-to-date on all things Mizzou when you subscribe to the Show Me Mizzou newsletter. Issues will arrive in your inbox every Tuesday, Wednesday and Thursday.